Neurological disorders

Neurological disorders significantly impact both patients and their families. Finding ways to improve their quality of life is a long and often complex journey involving collaboration, hard work, and dedication.   

Identifying potential therapeutic targets for the generation of life-changing drugs demands sensitive reagents to new and challenging targets, including post-translational modifications (PTMs) and aggregates. We understand that time is critical, so we want to help streamline your process.  

PTMs are critical in regulating neuronal function, and aberrant PTMs can lead to neurodegeneration, for example, tau hyperphosphorylation leading to Tauopathies. 

Tau is a biomarker for many neurodegenerative diseases, and its molecular diversity makes it a promising tool for monitoring therapeutics and differential diagnosis of dementia. We will work with you to provide robust reagents from our leading neurodegeneration portfolio, including many post-translational modifications of Tau to help advance its detailed characterization. 

Our deep expertise in neurological disorders means we can work with you to solve your problems quickly, helping you find detailed solutions that meet your needs throughout your discovery pipeline.  

We offer a wide choice of conjugation options, including carrier-free antibodies, to give you the flexibility to build multiplex panels that suit your experiment and generate clean, reproducible data. Additionally, we validate our products in relevant applications and sample types to ensure they work first time, every time, so you can finish experiments promptly. 

To help you harvest actionable data and smooth the transition from R&D to clinical applications, we also use recombinant technology to confirm the highest specificity and batch-to-batch consistency and offer a comprehensive range of ELISA kits and matched antibody pairs for follow-up studies.